In avian embryos, the migration behaviour of several cell populations, melanoblasts, Schwann cells, myogenic cells and axons after application of antibodies directed against the cell-attachment fragment of fibronectin (alpha-CAF) was investigated. The migration of the different cell types was influenced in different ways. 1. Epidermal melanoblasts did not colonize areas into which the antibody had been injected, i.e. distal to the grafting site. They frequently spread proximally to the back and neck, sometimes even as far as to the ipsilateral leg. When grafted to the dorsal side of the wing bud, melanoblasts never spread to the ventral side after injection of the antibody. Non-epidermal melanoblasts continued to migrate distally. 2. Grafted Schwann cells and host axons were not noticeably affected by the antibody injections. Both were found proximally and far distally to the grafting site, i.e. also within the injected area. 3. Myogenic cells were immobilized near the grafting site, where they differentiated biochemically, but sometimes only partially underwent fusion into myotubes. They participated in the formation of host muscle blastemas only immediately adjacent to the non-migratory cell population of the graft such as fibroblasts and cartilage. 4. The injected antibody could be localized up to 5 h after the application in the distal third of the limb bud. We conclude that migrating cell populations show differences in their fibronectin-dependence which probably reflect their use of fibronectin during migration.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00208193DOI Listing

Publication Analysis

Top Keywords

cell populations
12
grafting site
12
differences fibronectin-dependence
8
migrating cell
8
schwann cells
8
myogenic cells
8
cell
5
fibronectin-dependence migrating
4
populations avian
4
avian embryos
4

Similar Publications

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Background: Developing drugs for treating Alzheimer's disease (AD) has been extremely challenging and costly due to limited knowledge on underlying biological mechanisms and therapeutic targets. Repurposing drugs or their combination has shown potential in accelerating drug development due to the reduced drug toxicity while targeting multiple pathologies.

Method: To address the challenge in AD drug development, we developed a multi-task machine learning pipeline to integrate a comprehensive knowledge graph on biological/pharmacological interactions and multi-level evidence on drug efficacy, to identify repurposable drugs and their combination candidates RESULT: Using the drug embedding from the heterogeneous graph representation model, we ranked drug candidates based on evidence from post-treatment transcriptomic patterns, mechanistic efficacy in preclinical models, population-based treatment effect, and Phase 2/3 clinical trials.

View Article and Find Full Text PDF

Background: There are no cures for Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by elevation of beta-amyloid and tau proteins besides neuronal death and causing cognitive impairment. Phosphodiesterase 5 (PDE5) is a cyclic guanosine monophosphate-degrading enzyme involved in numerous biological pathways including those relevant to memory formation. PDE5 inhibition offers the potential to attenuate AD progression by acting at the downstream level of beta-amyloid and tau elevation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Good T Cells, Seoul, Mapo-gu, Korea, Republic of (South); YONSEI University, Seoul, Seodaemun-gu, Korea, Republic of (South).

Background: Neurodegenerative diseases, including Alzheimer's disease (AD), have been long thought to be independent of the peripheral immune system, but their pathogenesis status is functionally influenced by various T cell subsets in the periphery. Especially Treg cells are emerging as an important dynamic population in the brain, but the detailed immunological molecular and cellular processes are poorly characterized METHOD: We reported that the cell surface protein Lrig1 is enriched in Treg cells and is an essential regulator of the functions of Treg cells in vitro and in vivo. To evaluate the functional importance of Treg cells in AD pathogenesis, the modulating mAb specific to Lrig1 (GTC 310-01) via intravenous injection route was administered into 5xFAD or 6xTg mice, the genetic mouse model of AD, and the various AD symptoms were investigated.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Novo Nordisk A/S, Søborg, Denmark.

Background: Evidence suggests glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have therapeutic potential in Alzheimer's disease (AD). Cumulative evidence has indicated a potential reduction in cognitive decline in people with AD, while real-world evidence has shown decreased dementia risk in patients with type 2 diabetes. Non-clinical data reveal that GLP-1RAs impact neuroinflammation and other biological processes believed to be involved in AD pathophysiology, including effects on central and peripheral immune cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!